Merck & Co and partner Cardiome Pharma Corp have been granted marketing approval by European regulators for the intravenous formulation of their anti-arrhythmic Brinavess. The European Union, Iceland and Norway have given the green light to Brinavess (vernakalant) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. It can be used for non-surgery patients with AF of seven days or less and for post-cardiac surgery patients with AF of three days or less.
